



**Maidstone and  
Tunbridge Wells**  
NHS Trust

Ref: FOI/GS/ID 9514

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

20 November 2024

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Urothelial cancer (any stage).

*You asked: All questions are shown as received by the Trust.*

*1. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:*

- a. Atezolizumab (Tecentriq)*
- b. Avelumab (Bavencio)*
- c. Carboplatin single agent or in any other combination*
- d. Carboplatin with Gemcitabine*
- e. Carboplatin with Paclitaxel*
- f. Cisplatin single agent or in any other combination*
- g. Cisplatin with Gemcitabine*
- h. Cisplatin with Gemcitabine + Nivolumab (Opdivo)*
- i. Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)*
- j. Nivolumab (Opdivo)*
- k. Pembrolizumab (Keytruda)*
- l. Other active systemic anti-cancer therapy*
- m. Palliative care only*

*2. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?*

Trust response:

- 1.
- a. 0
- b. 6
- c. 0

- d. 4
- e. 0
- f. 0
- g. 8
- h. 0
- i. 0
- j. 0
- k. 0
- l. 4
- m. 0

2. The Trust does not have any active trials for urothelial cancer at this time.